Summary
Unable to verify manufacturing/supply/network statements against the provided FDA prescribing information excerpts; the provided label text does not support or mention these manufacturing/logistics claims.
Category Scores
Accurate Statements
Unsupported Statements
Kesimpta (ofatumumab) is manufactured by Novartis.
No supporting information regarding manufacturer identity is provided in the supplied prescribing information excerpts.
Kesimpta is made at Novartis manufacturing sites.
No manufacturing-site details are provided in the supplied prescribing information excerpts.
Supply of Kesimpta is handled under Novartis’s global production and distribution network for medicines.
No supply-chain, production, or distribution-network information is provided in the supplied prescribing information excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern manufacturing/supply logistics, which are not addressed in the provided label excerpts; they do not directly state dosing, contraindications, safety risks, or administration instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Manufacturing and distribution/network claims are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Remove or replace manufacturing/supply-network statements with information supported by the provided label (e.g., indications, dosage/administration, contraindications, warnings, adverse reactions).